Niagen Bioscience (NASDAQ:NAGE) Stock Price Target Cut by Canaccord Genuity Group

Key Points

• Canaccord Genuity cut its price target on Niagen Bioscience from $9 to $7 but maintained a Buy rating; the new target implies 234% upside from the prior close.
• Analyst sentiment remains broadly positive: MarketBeat reports an average Buy rating and a $9.33 consensus price target, while the stock traded at $2.10 and was near its 12-month low.
• Niagen’s latest quarter showed a loss of $0.01 per share, in line with estimates, on $27.19 million in revenue. Analysts expect full-year EPS of $0.08.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) had its price target lowered by stock analysts at Canaccord Genuity Group from $9.00 to $7.00 in a report released on Friday, Benzinga reports. The firm currently has a "buy" rating on the stock. Canaccord Genuity Group's price target would suggest a potential upside of 234.13% from the company's previous close.

NAGE has been the topic of a number of other reports. Roth Capital reissued a "buy" rating on shares of Niagen Bioscience in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Niagen Bioscience in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $9.33.

Niagen Bioscience Price Performance

Shares of NASDAQ NAGE traded down $0.01 during midday trading on Friday, hitting $2.10. 347,593 shares of the company's stock were exchanged, compared to its average volume of 838,099. The stock's 50 day moving average price is $2.79 and its 200-day moving average price is $3.85. The firm has a market cap of $166.85 million, a P/E ratio of 17.54 and a beta of 2.12. Niagen Bioscience has a twelve month low of $2.04 and a twelve month high of $7.28.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.01). Niagen Bioscience had a return on equity of 10.26% and a net margin of 8.37%. The business had revenue of $27.19 million during the quarter. On average, analysts expect that Niagen Bioscience will post 0.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Niagen Bioscience

Hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in Niagen Bioscience by 176.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 83,133 shares of the company's stock valued at $243,000 after acquiring an additional 53,110 shares during the last quarter. Kestra Advisory Services LLC grew its stake in shares of Niagen Bioscience by 81.5% in the 3rd quarter. Kestra Advisory Services LLC now owns 24,500 shares of the company's stock worth $72,000 after purchasing an additional 11,000 shares during the last quarter. State of Wyoming grew its stake in shares of Niagen Bioscience by 327.0% in the 3rd quarter. State of Wyoming now owns 63,108 shares of the company's stock worth $184,000 after purchasing an additional 48,329 shares during the last quarter. Abel Hall LLC acquired a new position in shares of Niagen Bioscience in the 3rd quarter worth approximately $99,000. Finally, SteelPeak Wealth LLC raised its holdings in shares of Niagen Bioscience by 2.2% in the 3rd quarter. SteelPeak Wealth LLC now owns 3,577,435 shares of the company's stock worth $10,446,000 after purchasing an additional 77,306 shares in the last quarter. 15.41% of the stock is currently owned by institutional investors and hedge funds.

Key Niagen Bioscience News

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Niagen outlined a three-year, 5,000-participant Mass General Brigham trial and is targeting early 2027 commercialization of NR malate, which could expand its product pipeline. Article: Niagen outlines trial and commercialization plans
• Positive Sentiment: Third-quarter direct-to-consumer sales on the company’s website rose 13% year over year; Tru Niagen generated $23.3 million of the $27.2 million in total sales, with a 62% gross margin. Article: Third-quarter 2026 financial results
• Neutral Sentiment: The Q3 earnings call was characterized as cash-flow positive, a potentially supportive indicator, though the headline does not provide figures to assess the strength or sustainability of cash generation. Article: Q3 earnings call highlights
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 EPS estimates from a profit of $0.02 to a loss of $0.02 per share for each quarter. It also lowered its FY2026 and FY2027 forecasts from $0.14 to $0.05 per share, signaling weaker expected earnings.
• Negative Sentiment: Niagen reported a Q3 loss of $0.01 per share, matching consensus but down from earnings of $0.05 a year earlier. Revenue was $27.2 million and reportedly fell short of estimates, adding to concerns about growth. Article: Niagen reports Q3 loss and misses revenue estimates

Niagen Bioscience Company Profile

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company's direct-to-consumer website and retail and distribution channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.